1541 — ImmuneOnco Biopharmaceuticals Shanghai Income Statement
0.000.00%
Last trade - 00:00- HK$2.66bn
- HK$2.00bn
- CNY74.15m
Annual income statement for ImmuneOnco Biopharmaceuticals Shanghai, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 5.07 | 0.538 | 0.386 | 74.1 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Unusual Expense / Income | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 737 | 403 | 378 | 387 |
| Operating Profit | -732 | -402 | -378 | -313 |
| Total Net Non Operating Interest Income / Expense | ||||
| Net Income Before Taxes | -733 | -403 | -379 | -317 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -733 | -403 | -379 | -317 |
| Minority Interest | ||||
| Net Income Before Extraordinary Items | ||||
| Net Income | -733 | -403 | -379 | -316 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -733 | -403 | -379 | -316 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -8.46 | -1.16 | -0.977 | -0.837 |